License and Collaboration Agreements - Schedule of Payments Allocated to Performance Obligations (Details) - USD ($) $ in Thousands	Dec. 12, 2021	Dec. 21, 2021
Allocation of transaction price
Deferred revenues as of 12/21/2021		$ 165,086
Option payment for Domvanalimab	$ 275,000
Option payment for Etrumadenant	250,000
Option payment for Quemliclustat	200,000
Total transaction price allocated to performance obligations	890,086
Allocation to performance obligations
Domvanalimab license	328,838
Etrumadenant license and R&D activities	218,722
Quemliclustat license and R&D activities	175,618
Domvanalimab R&D activities	34,528
Zimberelimab R&D and commercial activities	11,243
Access rights related to the Company's research and development pipeline	84,076
Material rights to option continuation periods	37,061
Total	$ 890,086